Hematological Oncology

Published by: Wiley Blackwell  

People

  1. Horwitz
    Horwitz
  2. Yahalom
    Yahalom
  3. Palomba
    Palomba
  4. Salles
    Salles
  5. Moskowitz
    Moskowitz
  6. Imber
    Imber
  7. Zelenetz
    Zelenetz
  8. Kumar
    Kumar
  9. Noy
    Noy
  10. Hajj
    Hajj

Groups

  1. Hematologic Malignancies, Division of (168)
  2. Department of Medicine (165)
  3. Center for Hematologic Malignancies (133)
  4. Lymphoma (110)
  5. Survivorship Research (55)
  6. Population Sciences Research Program (38)
  7. Radiation Oncology, Department of (34)
  8. Sloan Kettering Institute Postdocs (28)
  9. Executive Committee, Center for Hematologic Malignancies (26)
  10. Epidemiology and Biostatistics (24)
Search Within
  1. "Wiley Blackwell"
Formats
  1. Meeting Abstract (175)
  2. Journal Article (11)
  3. Conference Paper (4)
  4. Review (3)
  5. Research Letter (1)
Groups
  1. Hematologic Malignancies, Division of (168)
  2. Department of Medicine (165)
  3. Center for Hematologic Malignancies (133)
  4. Lymphoma (110)
  5. Survivorship Research (55)
  6. Population Sciences Research Program (38)

More Groups

People
  1. Steven Horwitz (38)
  2. Joachim Yahalom (34)
  3. Maria Palomba (30)
  4. Gilles Salles (27)
  5. Alison Moskowitz (23)
  6. Anas Younes (22)

More People

Years
  1. 2023 (66)
  2. 2022 (3)
  3. 2021 (32)
  4. 2020 (2)
  5. 2019 (48)
  6. 2018 (1)

More Years

Publishers
  1. Wiley Blackwell (194)

Results (194)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (LISO‐CEL) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
    Meeting Abstract

    Morschhauser, F.; Dahiya, S.; Palomba, M. L.; Garcia‐Sancho, A. M.; Reguera Ortega, J. L.; Kuruvilla, J.; Jager, U.; Cartron, G.; Izutsu, K.; Dreyling, M.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 3 trial of subcutaneous epcoritamab + R‐CHOP versus R‐CHOP in patients (pts) with newly diagnosed diffuse large B‐cell lymphoma (DLBCL): EPCORE DLBCL‐2
    Meeting Abstract

    Sehn, L. H.; Chamuleau, M.; Lenz, G.; Clausen, M. R.; Haioun, C.; Izutsu, K.; Davies, A.; Zhu, J.; Oki, T.; Szafer‐Glusman, E.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (LISO‐CEL) in R/R MCL: Primary analysis results from the MCL cohort of the single-arm, multicenter, seamless design transcend NHL 001 study
    Meeting Abstract

    Wang, M.; Siddiqi, T.; Gordon, L. I.; Kamdar, M.; Lunning, M.; Hirayama, A. V.; Abramson, J. S.; Arnason, J.; Ghosh, N.; Mehta, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Daratumumab and EPOCH for HIV+/‐ plasmablastic lymphoma: A feasibility study of the AIDS Malignancy Consortium (AMC 105)
    Meeting Abstract

    Noy, A.; Barta, S. K.; Tan, C. R.; Kwon, D.; Baiocchi, R.; Rubinstein, P.; Ambinder, R.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 trail of KT‐413, a degrader of IRAK4 and IMID substrates, in adult patients with relapsed or refractory B‐cell non‐Hodgkins's lymphomas
    Meeting Abstract

    Lue, J. K.; Stevens, D. A.; Ayers, E.; Dunleavy, K.; Mattour, A.; Mishkin, A.; McDonald, A.; Agarwal, S.; Henrick, P.; Perea, R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • A phase I study of split‐course bringing radiotherapy (SC‐BRT) prior to commercial CD19 CAR T‐cell therapies for patients with relapsed or refractory B‐cell lymphomas
    Meeting Abstract

    Imber, B. S.; Yahalom, J.; Palomba, M. L.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 study of PRT1419 (MCL1 inhibitor) as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory myeloid or B‐cell malignancies
    Meeting Abstract

    Zuniga, R. R.; Nair, S.; Keiffer, G.; Ravandi‐Kashani, F.; Goldberg, A. D.; Traer, E.; Frenzel, L. P.; Röllig, C.; Savickas, G.; Sun, W.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • ZUMA‐24: A phase 2, open-label study of axicabtagene ciloleucel in patients with relapsed/refractory large B‐cell lymphoma given outpatient with corticosteroids
    Meeting Abstract

    Leslie, L.; Tees, M.; Flinn, I. W.; Rodriguez, T. E.; Baird, J. H.; Deol, A.; Mead, M.; Bachier, C.; Rapoport, A. P.; McClune, B.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Upfront radiation therapy for post-stem cell transplant multiple myeloma patients with oligo‐relapse/progressive disease: Factors associated with favorable outcomes
    Meeting Abstract

    Fregonese, B.; Dreyfuss, A.; Imber, B.; Yahalom, J.; Hajj, C.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Lymph node and skin scoring growth kinetics predict outcomes in cutaneous T‐cell lymphoma: An interim analysis
    Meeting Abstract

    Fahmy, L. M.; Yang, H. R.; Zhou, M.; Beylergil, V.; Schreidah, C. M.; Kwinta, B. D.; Schwartz, L. H.; Fojo, A. T.; Bates, S. E.; Geskin, L. J.
    Hematological Oncology (2023)

    Fulltext@MSK | Save

    • Hematological Oncology – authorized name for:

    Name ISSN / ISBN Publisher
    Hematological Oncology 02780232 John Wiley & Sons
    Hematological Oncology 0278-0232 John Wiley & Sons
    Hematological Oncology 0278-0232 Wiley Blackwell
    Hematological Oncology 02780232 John Wiley & Sons
    Hematological Oncology 02780232 Unknown
    Hematological Oncology 0278-0232 John Wiley & Sons
    Hematological Oncology 02780232 John Wiley & Sons
    Hematological Oncology 0278-0232 Unknown
    Hematological Oncology 0278-0232 John Wiley & Sons
    Hematological Oncology 0278-0232 Wiley Blackwell